The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation

Lan Wang, Alexander Gural, Xiao Jian Sun, Xinyang Zhao, Fabiana Perna, Gang Huang, Megan A. Hatlen, Ly Vu, Fan Liu, Haiming Xu, Takashi Asai, Hao Xu, Tony Deblasio, Silvia Menendez, Francesca Voza, Yanwen Jiang, Philip A. Cole, Jinsong Zhang, Ari Melnick, Robert G. RoederStephen D. Nimer

Resultado de la investigación: Articlerevisión exhaustiva

166 Citas (Scopus)


The chromosomal translocations found in acute myelogenous leukemia (AML) generate oncogenic fusion transcription factors with aberrant transcriptional regulatory properties. Although therapeutic targeting of most leukemia fusion proteins remains elusive, the posttranslational modifications that control their function could be targetable. We found that AML1-ETO, the fusion protein generated by the t(8;21) translocation, is acetylated by the transcriptional coactivator p300 in leukemia cells isolated from t(8;21) AML patients, and that this acetylation is essential for its self-renewal-promoting effects in human cord blood CD34+ cells and its leukemogenicity in mouse models. Inhibition of p300 abrogates the acetylation of AML1-ETO and impairs its ability to promote leukemic transformation. Thus, lysine acetyltransferases represent a potential therapeutic target in AML.

Idioma originalEnglish (US)
Páginas (desde-hasta)765-769
Número de páginas5
EstadoPublished - ago. 5 2011
Publicado de forma externa

ASJC Scopus subject areas

  • General


Profundice en los temas de investigación de 'The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation'. En conjunto forman una huella única.

Citar esto